Dr. Mease is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1101 Madison St
Ste 1000
Seattle, WA 98104Phone+1 206-386-2001Fax+1 206-386-2083
Education & Training
- University of WashingtonFellowship, Rheumatology, 1981 - 1982
- University of WashingtonResidency, Internal Medicine, 1977 - 1981
- Stanford University School of MedicineClass of 1977
Certifications & Licensure
- WA State Medical License 1978 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- LIfetime Achievement Award National Psoriasis Foundation, 2019
- America's Top Doctors Castle Connolly, 2008-2014
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Rituxan With or Without Methotrexate in Psoriatic Arthritis Start of enrollment: 2006 Dec 01
- Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
- Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301 Start of enrollment: 2014 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.Philip J Mease, Shannon A Ferrante, Natalie J Shiff, Timothy P Fitzgerald, Soumya D Chakravarty
Advances in Therapy. 2024-12-02 - 1 citationsPersistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Y...Philip J Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R Soriano, Peter Nash
ACR Open Rheumatology. 2024-12-01 - Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials.Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn
Rheumatology and Therapy. 2024-12-01
Journal Articles
- Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical TrialsAlice Gottlieb, Philip Mease, Arthritis Care & Research
- Dual Inhibition of Tumour Necrosis Factor and Interleukin-17A with ABT-122: Open-Label Long-Term Extension Studies in Rheumatoid Arthritis or Psoriatic ArthritisPhilip Mease, MD, Rheumatology
- Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients with Psoriatic Arthritis: A Prospective Cohort StudyPhilip Mease, MD, Arthritis Care & Research
- Join now to see all
Authored Content
- Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020
Press Mentions
- Guselkumab Provides Long-Term Relief in Psoriatic ArthritisOctober 22nd, 2024
- UCB Announces a Head-to-Head Study Evaluating BIMZELX® (Bimekizumab) Versus SKYRIZI® (Risankizumab) in Active Psoriatic ArthritisSeptember 30th, 2024
- Managing Obesity & Fibromyalgia in Psoriatic DiseaseSeptember 9th, 2024
- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: